IL176339A0 - Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability - Google Patents

Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability

Info

Publication number
IL176339A0
IL176339A0 IL176339A IL17633906A IL176339A0 IL 176339 A0 IL176339 A0 IL 176339A0 IL 176339 A IL176339 A IL 176339A IL 17633906 A IL17633906 A IL 17633906A IL 176339 A0 IL176339 A0 IL 176339A0
Authority
IL
Israel
Prior art keywords
formulations
immunogenic composition
hydrophobic proteins
improved tolerability
tolerability
Prior art date
Application number
IL176339A
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL176339A0 publication Critical patent/IL176339A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
IL176339A 2003-12-30 2006-06-15 Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability IL176339A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53312203P 2003-12-30 2003-12-30
PCT/US2004/043792 WO2005065708A2 (en) 2003-12-30 2004-12-28 Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability

Publications (1)

Publication Number Publication Date
IL176339A0 true IL176339A0 (en) 2006-10-05

Family

ID=34748856

Family Applications (1)

Application Number Title Priority Date Filing Date
IL176339A IL176339A0 (en) 2003-12-30 2006-06-15 Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability

Country Status (13)

Country Link
US (1) US7608278B2 (en)
EP (1) EP1699482A2 (en)
JP (1) JP2007517057A (en)
KR (1) KR20060108739A (en)
CN (1) CN1901935A (en)
AU (1) AU2004312067A1 (en)
BR (1) BRPI0417938A (en)
CA (1) CA2551896A1 (en)
IL (1) IL176339A0 (en)
MX (1) MXPA06007635A (en)
TW (1) TW200526244A (en)
WO (1) WO2005065708A2 (en)
ZA (1) ZA200605393B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
US9814422B2 (en) 2007-08-06 2017-11-14 The Regents Of The University Of California Compositions for solubilizing cells and/or tissue
JP5731109B2 (en) * 2009-07-09 2015-06-10 東亞合成株式会社 Method for producing antibody against hydrophobic peptide
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
HUE052850T2 (en) 2010-08-23 2021-05-28 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR20130047749A (en) 2010-08-30 2013-05-08 에프. 호프만-라 로슈 아게 Method for producing a tetranectin-apolipoprotein a-i lipid particle, the lipid particle itself and its use
MX2013001539A (en) 2010-08-30 2013-03-18 Hoffmann La Roche Method for producing a tetranectin-apolipoprotein a-i particle, the lipid particle obtained therewith and its use.
ES2585328T5 (en) 2010-09-10 2022-12-14 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
EP2662387A4 (en) * 2011-01-07 2015-08-05 Seiko Epson Corp Antibody to signal peptide of amyloid precursor protein
JP6207507B2 (en) 2011-08-25 2017-10-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Shortened tetranectin-apolipoprotein AI fusion protein, lipid particles containing the same, and uses thereof
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
MX369625B (en) * 2012-05-16 2019-11-14 Univ California Compositions for solubilizing cells and/or tissue.
JP6066222B2 (en) 2012-05-28 2017-01-25 東亞合成株式会社 Antibacterial peptides and their use
EP2879691B1 (en) 2012-08-06 2019-03-27 Biogen MA Inc. Methods for inactivating enveloped viruses
WO2014061749A1 (en) 2012-10-18 2014-04-24 東亞合成株式会社 Synthetic peptide capable of suppressing expression of tnf receptor type-2, and use thereof
JP6446377B2 (en) 2013-03-08 2018-12-26 ファイザー・インク Immunogenic fusion polypeptide
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112017017460A2 (en) 2015-02-19 2018-04-10 Pfizer Inc. neisseria meningitidis compositions and methods thereof
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3809796A1 (en) * 1988-03-23 1989-10-05 Wolfgang Prof Dr Med Bredt PROCESS FOR CLEANING A 168 KD PROTEIN OF MYCOPLASMA PNEUMONIAE
PT624376E (en) 1993-05-13 2000-07-31 American Cyanamid Co PREPARATION AND UTILIZATION OF EXTERNAL MEMBRANE PROTEINS DEFICIATED IN GRAM-NEGATIVE COCONUTS
WO2000045841A2 (en) 1999-02-05 2000-08-10 Merck & Co., Inc. Human papilloma virus vaccine formulations

Also Published As

Publication number Publication date
BRPI0417938A (en) 2007-04-17
JP2007517057A (en) 2007-06-28
CA2551896A1 (en) 2005-07-21
MXPA06007635A (en) 2007-01-30
CN1901935A (en) 2007-01-24
WO2005065708A2 (en) 2005-07-21
US7608278B2 (en) 2009-10-27
ZA200605393B (en) 2009-12-30
US20070122433A1 (en) 2007-05-31
KR20060108739A (en) 2006-10-18
WO2005065708A3 (en) 2005-10-20
TW200526244A (en) 2005-08-16
AU2004312067A1 (en) 2005-07-21
EP1699482A2 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
IL176339A0 (en) Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
PL1682091T3 (en) Compositions of lipids and cationic peptides
IL182495A0 (en) Orthogonal translation components for the in vivo incorporation of unnatural amino acids
PL1817048T3 (en) Stable formulations of insulinoptropic peptides
PL377614A1 (en) Compositions comprising fatty acids and amino acids
HK1203558A1 (en) In vivo incorporation of unnatural amino acids
IL218357A0 (en) Compositions and methods of using angiopoietin-like 4 protein
IL175844A0 (en) Improved stability of progestogen formulations
EP1631308A4 (en) Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
IL174420A0 (en) Stabilized formulations of phosphatidylserine
HK1119951A1 (en) Methods and compositions for oral administration of proteins
IL151942A0 (en) Compositions and methods for enhancing immunogenicity of antigens
HK1081404A1 (en) Acidic compositions comprising protein and fiber and processes of their preparation
GB0323965D0 (en) Immunogenic compositions
EP1858532A4 (en) Compositions and methods for less immunogenic protein formulations
AU2003230761A1 (en) Polymeric micelle formulations of hydrophobic compounds and methods
AU5577201A (en) Immunogenic pneumococcal protein and vaccine compositions thereof
PL1663928T3 (en) Preparation of an alkoxylate composition
IL175746A0 (en) Oral formulations of desoxypeganine and uses thereof
EP1684798A4 (en) Recombinant intracellular pathogen immunogenic compositions and methods for use
GB2412338B (en) Surface preparation of an implant
EP1670893A4 (en) Immunogenic hiv compositions and related methods
IL172758A0 (en) Pharmaceutical compositions containing balaglitazone and methods for the preparation thereof
HUP0400737A3 (en) Use of l-carnitine for preparation of compositions for stabilizing the proteins
AP2004003081A0 (en) Immunogenic formulations of variable peptidic epitopes and for preparation thereof